ArticleJournal of cancer research and clinical oncology2026
Interventional management of unresectable pancreatic cancer using transarterial chemoembolization and microwave ablation: a single-center evaluation over 12 years.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study is to evaluate the safety and clinical outcomes of combined transarterial chemoembolization (TACE) and microwave ablation (MWA) as well as TACE monotherapy in patients with unresectable pancreatic cancer. MATERIALS AND
methodsBetween 2010 and 2023, 150 patients with unresectable locally advanced pancreatic cancer were included in this retrospective single-center study and treated with either combined TACE and MWA (Group A, n = 67) or TACE alone (Group B, n = 83). In Group A, 23/67 (34.3%) patients presented with metastatic disease and in Group B 45/83 (54.2%) patients had metastatic disease. A total of 222 TACE procedures and 71 MWA procedures were performed in Group A, while 250 TACE procedures were performed in Group B. Follow-up was performed using contrast-enhanced cross-sectional imaging and clinical evaluation. Tumor response and overall survival were analyzed.
resultsThe mean tumor diameter was 3.4 ± 0.9 cm in Group A and 4.9 ± 1.3 cm in Group B. No major complications occurred in either treatment group. Minor hemorrhage following MWA was observed in 4/71 ablations (5.6%) without further clinical consequence. In Group A, follow-up imaging was available for 47/67 patients, with local tumor progression observed in 5/47 patients (10.6%). The 1-year overall survival rate was 69.4%, with a median overall survival time of 14.6 months (95% CI 12.6–16.7 months). In Group B, follow-up imaging was available for all 83 patients, with local tumor progression observed in 8/83 patients (9.6%). The 1-year overall survival rate was 43.6%, with a median overall survival time of 9.0 months (95% CI 3.3–14.7 months).
conclusionTACE and MWA were safe locoregional treatments for patients with unresectable pancreatic cancer. Both treatment protocols, including the combination of TACE with MWA and TACE as monotherapy, were effective and showed promising results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.